The Skin Diseases Treatment Market value is projected to reach US$ 4.89 Bn 2030 at the end of the forecast period and it is expected to grow at the CAGR of 3.67%.Skin Diseases Treatment Market Overview:
Skin Diseases Treatment or Dermatology is a fast-paced industry over the past decade owing to the rising prevalence of skin diseases. Various innovative therapies are being developed to combat skin diseases. Various factors are contributing to the growth of the Skin Disease Treatment market, which includes demand for topical dermatological drugs. Also, rising awareness about various skin diseases coupled with rapid diagnosis techniques, surge in skin cancer prominently drive the market upwards. However, lack of awareness about drugs used in the treatment of skin diseases and stringent government regulations may restrain the market growth. Development of innovative products and increase in the number of mergers and acquisitions by key vendors are expected to provide numerous opportunities for this market. Artificial or bioengineered skin substitutes have made revolutionary developments in skin disease treatment.To know about the Research Methodology :- Request Free Sample Report
Skin Diseases Treatment Market Regional Analysis:
North America holds the most prominent market share for skin disease treatment and is expected to dominate throughout the forecast period. Following this trend, Europe is also expected to dominate the global skin disease treatment market in the upcoming years. Technological advances and the availability of the latest products and devices for skin disease treatment are the key factors that drive the demand of the market in these regions. APAC is also expected to witness strong growth in upcoming years due to increasing awareness, massive population base and ongoing technological advancements. Growing medical tourism in countries like Thailand, India, Singapore, South Korea, and Malaysia has spurred the demand for skin disease treatment from countries around the world.Skin Diseases Treatment Market Segment analysis:
Autoimmune skin diseases segment grows remarkably owing to the development of new therapies, dermatological drugs are expected to add revenue in the autoimmune skin diseases treatment market. Autoimmune skin diseases treatment consists of drug a class act on autoimmune skin diseases which are a heterogeneous group of conditions clinically characterized by blisters and erosions on the skin and close-to-surface mucous membranes. The objective of the report is to present a comprehensive analysis of the Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.The report also helps in understanding Global Market dynamics, structure by analyzing the market segments and project the Global Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Market make the report investor’s guide.
Skin Diseases Treatment Market Scope: Inquire before buying
Skin Diseases Treatment Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: US $ 3.80 Bn. Forecast Period 2024 to 2030 CAGR: 3.67% Market Size in 2030: US $ 4.89 Bn. Segments Covered: by Product Type Medicated creams and Ointments Antibiotics and Vitamins Steroids Laser Therapy Antifungals by Type of Diseases Autoimmune skin diseases Genetic skin diseases Allergic skin diseases Infectious Skin diseases Skin cancers by End-Users Dermatology clinics Skincare clinics Hospitals Aesthetic centres Skin Diseases Treatment Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe) Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina, Columbia and Rest of South America)Key players operating in the skin Diseases Treatment market:
1. Pfizer Inc. 2. Allergen Plc. 3. Celgene Corporation 4. Abbvie Inc. 5. Eli Lilly and Company 6. GlaxoSmithKline Plc. 7. Galderma 8. Incyte corporation 9. Valeant Pharmaceuticals International Inc. 10. Almirall S.A. 11. Bayer AG 12. Johnson & Johnson 13. Novartis AG 14. AstraZeneca 15. Amgen Inc. 16. Merck KGaA 17. Cipher pharmaceuticals Frequently Asked Questions: 1. Which region has the largest share in Global Market? Ans: North America region held the highest share in 2023. 2. What is the growth rate of Global Skin Diseases Treatment Market? Ans: The Global Skin Diseases Treatment Market is growing at a CAGR of 3.67% during forecasting period 2024-2030. 3. What is scope of the Global Skin Diseases Treatment Market report? Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Market? Ans: The important key players in the Global Market are – Pfizer Inc., Allergen Plc., Celgene Corporation, Abbvie Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Galderma, Incyte corporation, Valeant Pharmaceuticals International Inc., Almirall S.A., Bayer AG, Johnson & Johnson, Novartis AG, AstraZeneca, Amgen Inc., Merck KGaA, Cipher pharmaceuticals, Janssen biotech, Kaken Pharmaceuticals, and Regeneron pharmaceuticals Inc. 5. What is the study period of this Market? Ans: The Global Market is studied from 2023 to 2030.
Global Skin Diseases Treatment Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Skin Diseases Treatment Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Skin Diseases Treatment Analysis and Forecast 6.1. Skin Diseases Treatment Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Skin Diseases Treatment Analysis and Forecast, By Product Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Skin Diseases Treatment Value Share Analysis, By Product Type 7.4. Skin Diseases Treatment Size (US$ Mn) Forecast, By Product Type 7.5. Skin Diseases Treatment Analysis, By Product Type 7.6. Skin Diseases Treatment Attractiveness Analysis, By Product Type 8. Global Skin Diseases Treatment Analysis and Forecast, By Type of Diseases 8.1. Introduction and Definition 8.2. Key Findings 8.3. Skin Diseases Treatment Value Share Analysis, By Type of Diseases 8.4. Skin Diseases Treatment Size (US$ Mn) Forecast, By Type of Diseases 8.5. Skin Diseases Treatment Analysis, By Type of Diseases 8.6. Skin Diseases Treatment Attractiveness Analysis, By Type of Diseases 9. Global Skin Diseases Treatment Analysis and Forecast By End-Users 9.1. Introduction and Definition 9.2. Key Findings 9.3. Skin Diseases Treatment Value Share Analysis, By End-Users 9.4. Skin Diseases Treatment Size (US$ Mn) Forecast, By End-Users 9.5. Skin Diseases Treatment Analysis, By End-Users 9.6. Skin Diseases Treatment Attractiveness Analysis, By End-Users 10. Global Skin Diseases Treatment Analysis, By Region 10.1. Skin Diseases Treatment Value Share Analysis, By Region 10.2. Skin Diseases Treatment Size (US$ Mn) Forecast, By Region 10.3. Skin Diseases Treatment Attractiveness Analysis, By Region 11. North America Skin Diseases Treatment Analysis 11.1. Key Findings 11.2. North America Skin Diseases Treatment Overview 11.3. North America Skin Diseases Treatment Value Share Analysis, By Product Type 11.4. North America Skin Diseases Treatment Forecast, By Product Type 11.4.1. Medicated creams and Ointments 11.4.2. Antibiotics and Vitamins 11.4.3. Steroids 11.4.4. Laser Therapy 11.4.5. Antifungals 11.5. North America Skin Diseases Treatment Value Share Analysis, By Type of Diseases 11.6. North America Skin Diseases Treatment Forecast, By Type of Diseases 11.6.1. Autoimmune skin diseases 11.6.2. Genetic skin diseases 11.6.3. Allergic skin diseases 11.6.4. Infectious Skin diseases 11.6.5. Skin cancers 11.7. North America Skin Diseases Treatment Value Share Analysis, By End-Users 11.8. North America Skin Diseases Treatment Forecast, By End-Users 11.8.1. Dermatology clinics 11.8.2. Skincare clinics 11.8.3. Hospitals 11.8.4. Aesthetic centres 11.9. North America Skin Diseases Treatment Value Share Analysis, By Country 11.10. North America Skin Diseases Treatment Forecast, By Country 11.10.1. U.S. 11.10.2. Canada 11.10.3. Mexico 11.11. North America Skin Diseases Treatment Analysis, By Country 11.12. U.S. Skin Diseases Treatment Forecast, By Product Type 11.12.1. Medicated creams and Ointments 11.12.2. Antibiotics and Vitamins 11.12.3. Steroids 11.12.4. Laser Therapy 11.12.5. Antifungals 11.13. U.S. Skin Diseases Treatment Forecast, By Type of Diseases 11.13.1. Autoimmune skin diseases 11.13.2. Genetic skin diseases 11.13.3. Allergic skin diseases 11.13.4. Infectious Skin diseases 11.13.5. Skin cancers 11.14. U.S. Skin Diseases Treatment Forecast, By End-Users 11.14.1. Dermatology clinics 11.14.2. Skincare clinics 11.14.3. Hospitals 11.14.4. Aesthetic centres 11.15. Canada Skin Diseases Treatment Forecast, By Product Type 11.15.1. Medicated creams and Ointments 11.15.2. Antibiotics and Vitamins 11.15.3. Steroids 11.15.4. Laser Therapy 11.15.5. Antifungals 11.16. Canada Skin Diseases Treatment Forecast, By Type of Diseases 11.16.1. Autoimmune skin diseases 11.16.2. Genetic skin diseases 11.16.3. Allergic skin diseases 11.16.4. Infectious Skin diseases 11.16.5. Skin cancers 11.17. Canada Skin Diseases Treatment Forecast, By End-Users 11.17.1. Dermatology clinics 11.17.2. Skincare clinics 11.17.3. Hospitals 11.17.4. Aesthetic centres 11.18. Mexico Skin Diseases Treatment Forecast, By Product Type 11.18.1. Medicated creams and Ointments 11.18.2. Antibiotics and Vitamins 11.18.3. Steroids 11.18.4. Laser Therapy 11.18.5. Antifungals 11.19. Mexico Skin Diseases Treatment Forecast, By Type of Diseases 11.19.1. Autoimmune skin diseases 11.19.2. Genetic skin diseases 11.19.3. Allergic skin diseases 11.19.4. Infectious Skin diseases 11.19.5. Skin cancers 11.20. Mexico Skin Diseases Treatment Forecast, By End-Users 11.20.1. Dermatology clinics 11.20.2. Skincare clinics 11.20.3. Hospitals 11.20.4. Aesthetic centres 11.21. North America Skin Diseases Treatment Attractiveness Analysis 11.21.1. By Product Type 11.21.2. By Type of Diseases 11.21.3. By End-Users 11.22. PEST Analysis 11.23. Key Trends 11.24. Key Developments 12. Europe Skin Diseases Treatment Analysis 12.1. Key Findings 12.2. Europe Skin Diseases Treatment Overview 12.3. Europe Skin Diseases Treatment Value Share Analysis, By Product Type 12.4. Europe Skin Diseases Treatment Forecast, By Product Type 12.4.1. Medicated creams and Ointments 12.4.2. Antibiotics and Vitamins 12.4.3. Steroids 12.4.4. Laser Therapy 12.4.5. Antifungals 12.5. Europe Skin Diseases Treatment Value Share Analysis, By Type of Diseases 12.6. Europe Skin Diseases Treatment Forecast, By Type of Diseases 12.6.1. Autoimmune skin diseases 12.6.2. Genetic skin diseases 12.6.3. Allergic skin diseases 12.6.4. Infectious Skin diseases 12.6.5. Skin cancers 12.7. Europe Skin Diseases Treatment Value Share Analysis, By End-Users 12.8. Europe Skin Diseases Treatment Forecast, By End-Users 12.8.1. Dermatology clinics 12.8.2. Skincare clinics 12.8.3. Hospitals 12.8.4. Aesthetic centres 12.9. Europe Skin Diseases Treatment Value Share Analysis, By Country 12.10. Europe Skin Diseases Treatment Forecast, By Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Sweden 12.10.7. CIS countries 12.10.8. Rest of Europe 12.11. Germany Skin Diseases Treatment Forecast, By Product Type 12.11.1. Medicated creams and Ointments 12.11.2. Antibiotics and Vitamins 12.11.3. Steroids 12.11.4. Laser Therapy 12.11.5. Antifungals 12.12. Germany Skin Diseases Treatment Forecast, By Type of Diseases 12.12.1. Autoimmune skin diseases 12.12.2. Genetic skin diseases 12.12.3. Allergic skin diseases 12.12.4. Infectious Skin diseases 12.12.5. Skin cancers 12.13. Germany Skin Diseases Treatment Forecast, By End-Users 12.13.1. Dermatology clinics 12.13.2. Skincare clinics 12.13.3. Hospitals 12.13.4. Aesthetic centres 12.14. U.K. Skin Diseases Treatment Forecast, By Product Type 12.14.1. Medicated creams and Ointments 12.14.2. Antibiotics and Vitamins 12.14.3. Steroids 12.14.4. Laser Therapy 12.14.5. Antifungals 12.15. U.K. Skin Diseases Treatment Forecast, By Type of Diseases 12.15.1. Autoimmune skin diseases 12.15.2. Genetic skin diseases 12.15.3. Allergic skin diseases 12.15.4. Infectious Skin diseases 12.15.5. Skin cancers 12.16. U.K. Skin Diseases Treatment Forecast, By End-Users 12.16.1. Dermatology clinics 12.16.2. Skincare clinics 12.16.3. Hospitals 12.16.4. Aesthetic centres 12.17. France Skin Diseases Treatment Forecast, By Product Type 12.17.1. Medicated creams and Ointments 12.17.2. Antibiotics and Vitamins 12.17.3. Steroids 12.17.4. Laser Therapy 12.17.5. Antifungals 12.18. France Skin Diseases Treatment Forecast, By Type of Diseases 12.18.1. Autoimmune skin diseases 12.18.2. Genetic skin diseases 12.18.3. Allergic skin diseases 12.18.4. Infectious Skin diseases 12.18.5. Skin cancers 12.19. France Skin Diseases Treatment Forecast, By End-Users 12.19.1. Dermatology clinics 12.19.2. Skincare clinics 12.19.3. Hospitals 12.19.4. Aesthetic centres 12.20. Italy Skin Diseases Treatment Forecast, By Product Type 12.20.1. Medicated creams and Ointments 12.20.2. Antibiotics and Vitamins 12.20.3. Steroids 12.20.4. Laser Therapy 12.20.5. Antifungals 12.21. Italy Skin Diseases Treatment Forecast, By Type of Diseases 12.21.1. Autoimmune skin diseases 12.21.2. Genetic skin diseases 12.21.3. Allergic skin diseases 12.21.4. Infectious Skin diseases 12.21.5. Skin cancers 12.22. Italy Skin Diseases Treatment Forecast, By End-Users 12.22.1. Dermatology clinics 12.22.2. Skincare clinics 12.22.3. Hospitals 12.22.4. Aesthetic centres 12.23. Spain Skin Diseases Treatment Forecast, By Product Type 12.23.1. Medicated creams and Ointments 12.23.2. Antibiotics and Vitamins 12.23.3. Steroids 12.23.4. Laser Therapy 12.23.5. Antifungals 12.24. Spain Skin Diseases Treatment Forecast, By Type of Diseases 12.24.1. Autoimmune skin diseases 12.24.2. Genetic skin diseases 12.24.3. Allergic skin diseases 12.24.4. Infectious Skin diseases 12.24.5. Skin cancers 12.25. Spain Skin Diseases Treatment Forecast, By End-Users 12.25.1. Dermatology clinics 12.25.2. Skincare clinics 12.25.3. Hospitals 12.25.4. Aesthetic centres 12.26. Sweden Skin Diseases Treatment Forecast, By Product Type 12.26.1. Medicated creams and Ointments 12.26.2. Antibiotics and Vitamins 12.26.3. Steroids 12.26.4. Laser Therapy 12.26.5. Antifungals 12.27. Sweden Skin Diseases Treatment Forecast, By Type of Diseases 12.27.1. Autoimmune skin diseases 12.27.2. Genetic skin diseases 12.27.3. Allergic skin diseases 12.27.4. Infectious Skin diseases 12.27.5. Skin cancers 12.28. Sweden Skin Diseases Treatment Forecast, By End-Users 12.28.1. Dermatology clinics 12.28.2. Skincare clinics 12.28.3. Hospitals 12.28.4. Aesthetic centres 12.29. CIS countries Skin Diseases Treatment Forecast, By Product Type 12.29.1. Medicated creams and Ointments 12.29.2. Antibiotics and Vitamins 12.29.3. Steroids 12.29.4. Laser Therapy 12.29.5. Antifungals 12.30. CIS countries Skin Diseases Treatment Forecast, By Type of Diseases 12.30.1. Autoimmune skin diseases 12.30.2. Genetic skin diseases 12.30.3. Allergic skin diseases 12.30.4. Infectious Skin diseases 12.30.5. Skin cancers 12.31. CIS countries Skin Diseases Treatment Forecast, By End-Users 12.31.1. Dermatology clinics 12.31.2. Skincare clinics 12.31.3. Hospitals 12.31.4. Aesthetic centres 12.32. Rest of Europe Skin Diseases Treatment Forecast, By Product Type 12.32.1. Medicated creams and Ointments 12.32.2. Antibiotics and Vitamins 12.32.3. Steroids 12.32.4. Laser Therapy 12.32.5. Antifungals 12.33. Rest of Europe Skin Diseases Treatment Forecast, By Type of Diseases 12.33.1. Autoimmune skin diseases 12.33.2. Genetic skin diseases 12.33.3. Allergic skin diseases 12.33.4. Infectious Skin diseases 12.33.5. Skin cancers 12.34. Rest of Europe Skin Diseases Treatment Forecast, By End-Users 12.34.1. Dermatology clinics 12.34.2. Skincare clinics 12.34.3. Hospitals 12.34.4. Aesthetic centres 12.35. Europe Skin Diseases Treatment Attractiveness Analysis 12.35.1. By Type of Diseases 12.35.2. By Product Type 12.35.3. By End-Users 12.36. PEST Analysis 12.37. Key Trends 12.38. Key Developments 13. Asia Pacific Skin Diseases Treatment Analysis 13.1. Key Findings 13.2. Asia Pacific Skin Diseases Treatment Overview 13.3. Asia Pacific Skin Diseases Treatment Value Share Analysis, By Product Type 13.4. Asia Pacific Skin Diseases Treatment Forecast, By Product Type 13.4.1. Medicated creams and Ointments 13.4.2. Antibiotics and Vitamins 13.4.3. Steroids 13.4.4. Laser Therapy 13.4.5. Antifungals 13.5. Asia Pacific Skin Diseases Treatment Value Share Analysis, By Type of Diseases 13.6. Asia Pacific Skin Diseases Treatment Forecast, By Type of Diseases 13.6.1. Autoimmune skin diseases 13.6.2. Genetic skin diseases 13.6.3. Allergic skin diseases 13.6.4. Infectious Skin diseases 13.6.5. Skin cancers 13.7. Asia Pacific Skin Diseases Treatment Value Share Analysis, By End-Users 13.8. Asia Pacific Skin Diseases Treatment Forecast, By End-Users 13.8.1. Dermatology clinics 13.8.2. Skincare clinics 13.8.3. Hospitals 13.8.4. Aesthetic centres 13.9. Asia Pacific Skin Diseases Treatment Value Share Analysis, By Country 13.10. Asia Pacific Skin Diseases Treatment Forecast, By Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. South Korea 13.10.5. Australia 13.10.6. ASEAN 13.10.7. Rest of Asia Pacific 13.11. Asia Pacific Skin Diseases Treatment Analysis, By Country 13.12. China Skin Diseases Treatment Forecast, By Product Type 13.12.1. Medicated creams and Ointments 13.12.2. Antibiotics and Vitamins 13.12.3. Steroids 13.12.4. Laser Therapy 13.12.5. Antifungals 13.13. China Skin Diseases Treatment Forecast, By Type of Diseases 13.13.1. Autoimmune skin diseases 13.13.2. Genetic skin diseases 13.13.3. Allergic skin diseases 13.13.4. Infectious Skin diseases 13.13.5. Skin cancers 13.14. China Skin Diseases Treatment Forecast, By End-Users 13.14.1. Dermatology clinics 13.14.2. Skincare clinics 13.14.3. Hospitals 13.14.4. Aesthetic centres 13.15. India Skin Diseases Treatment Forecast, By Product Type 13.15.1. Medicated creams and Ointments 13.15.2. Antibiotics and Vitamins 13.15.3. Steroids 13.15.4. Laser Therapy 13.15.5. Antifungals 13.16. India Skin Diseases Treatment Forecast, By Type of Diseases 13.16.1. Autoimmune skin diseases 13.16.2. Genetic skin diseases 13.16.3. Allergic skin diseases 13.16.4. Infectious Skin diseases 13.16.5. Skin cancers 13.17. India Skin Diseases Treatment Forecast, By End-Users 13.17.1. Dermatology clinics 13.17.2. Skincare clinics 13.17.3. Hospitals 13.17.4. Aesthetic centres 13.18. Japan Skin Diseases Treatment Forecast, By Product Type 13.18.1. Medicated creams and Ointments 13.18.2. Antibiotics and Vitamins 13.18.3. Steroids 13.18.4. Laser Therapy 13.18.5. Antifungals 13.19. Japan Skin Diseases Treatment Forecast, By Type of Diseases 13.19.1. Autoimmune skin diseases 13.19.2. Genetic skin diseases 13.19.3. Allergic skin diseases 13.19.4. Infectious Skin diseases 13.19.5. Skin cancers 13.20. Japan Skin Diseases Treatment Forecast, By End-Users 13.20.1. Dermatology clinics 13.20.2. Skincare clinics 13.20.3. Hospitals 13.20.4. Aesthetic centres 13.21. South Korea Skin Diseases Treatment Forecast, By Product Type 13.21.1. Medicated creams and Ointments 13.21.2. Antibiotics and Vitamins 13.21.3. Steroids 13.21.4. Laser Therapy 13.21.5. Antifungals 13.22. South Korea Skin Diseases Treatment Forecast, By Type of Diseases 13.22.1. Autoimmune skin diseases 13.22.2. Genetic skin diseases 13.22.3. Allergic skin diseases 13.22.4. Infectious Skin diseases 13.22.5. Skin cancers 13.23. South Korea Skin Diseases Treatment Forecast, By End-Users 13.23.1. Dermatology clinics 13.23.2. Skincare clinics 13.23.3. Hospitals 13.23.4. Aesthetic centres 13.24. Australia Skin Diseases Treatment Forecast, By Product Type 13.24.1. Medicated creams and Ointments 13.24.2. Antibiotics and Vitamins 13.24.3. Steroids 13.24.4. Laser Therapy 13.24.5. Antifungals 13.25. Australia Skin Diseases Treatment Forecast, By Type of Diseases 13.25.1. Autoimmune skin diseases 13.25.2. Genetic skin diseases 13.25.3. Allergic skin diseases 13.25.4. Infectious Skin diseases 13.25.5. Skin cancers 13.26. Australia Skin Diseases Treatment Forecast, By End-Users 13.26.1. Dermatology clinics 13.26.2. Skincare clinics 13.26.3. Hospitals 13.26.4. Aesthetic centres 13.27. ASEAN Skin Diseases Treatment Forecast, By Product Type 13.27.1. Medicated creams and Ointments 13.27.2. Antibiotics and Vitamins 13.27.3. Steroids 13.27.4. Laser Therapy 13.27.5. Antifungals 13.28. ASEAN Skin Diseases Treatment Forecast, By Type of Diseases 13.28.1. Autoimmune skin diseases 13.28.2. Genetic skin diseases 13.28.3. Allergic skin diseases 13.28.4. Infectious Skin diseases 13.28.5. Skin cancers 13.29. ASEAN Skin Diseases Treatment Forecast, By End-Users 13.29.1. Dermatology clinics 13.29.2. Skincare clinics 13.29.3. Hospitals 13.29.4. Aesthetic centres 13.30. Rest of Asia Pacific Skin Diseases Treatment Forecast, By Product Type 13.30.1. Medicated creams and Ointments 13.30.2. Antibiotics and Vitamins 13.30.3. Steroids 13.30.4. Laser Therapy 13.30.5. Antifungals 13.31. Rest of Asia Pacific Skin Diseases Treatment Forecast, By Type of Diseases 13.31.1. Autoimmune skin diseases 13.31.2. Genetic skin diseases 13.31.3. Allergic skin diseases 13.31.4. Infectious Skin diseases 13.31.5. Skin cancers 13.32. Rest of Asia Pacific Skin Diseases Treatment Forecast, By End-Users 13.32.1. Dermatology clinics 13.32.2. Skincare clinics 13.32.3. Hospitals 13.32.4. Aesthetic centres 13.33. Asia Pacific Skin Diseases Treatment Attractiveness Analysis 13.33.1. By Product Type 13.33.2. By Type of Diseases 13.33.3. By End-Users 13.34. PEST Analysis 13.35. Key Trends 13.36. Key Developments 14. Middle East & Africa Skin Diseases Treatment Analysis 14.1. Key Findings 14.2. Middle East & Africa Skin Diseases Treatment Overview 14.3. Middle East & Africa Skin Diseases Treatment Value Share Analysis, By Product Type 14.4. Middle East & Africa Skin Diseases Treatment Forecast, By Product Type 14.4.1. Medicated creams and Ointments 14.4.2. Antibiotics and Vitamins 14.4.3. Steroids 14.4.4. Laser Therapy 14.4.5. Antifungals 14.5. Middle East & Africa Skin Diseases Treatment Value Share Analysis, By Type of Diseases 14.6. Middle East & Africa Skin Diseases Treatment Forecast, By Type of Diseases 14.6.1. Autoimmune skin diseases 14.6.2. Genetic skin diseases 14.6.3. Allergic skin diseases 14.6.4. Infectious Skin diseases 14.6.5. Skin cancers 14.7. Middle East & Africa Skin Diseases Treatment Value Share Analysis, By End-Users 14.8. Middle East & Africa Skin Diseases Treatment Forecast, By End-Users 14.8.1. Dermatology clinics 14.8.2. Skincare clinics 14.8.3. Hospitals 14.8.4. Aesthetic centres 14.9. Middle East & Africa Skin Diseases Treatment Value Share Analysis, By Country 14.10. Middle East & Africa Skin Diseases Treatment Forecast, By Country 14.10.1. GCC Countries 14.10.2. South Africa 14.10.3. Nigeria 14.10.4. Egypt 14.10.5. Rest of Middle East & Africa 14.11. Middle East & Africa Skin Diseases Treatment Analysis, By Country 14.12. GCC Countries Skin Diseases Treatment Forecast, By Product Type 14.12.1. Medicated creams and Ointments 14.12.2. Antibiotics and Vitamins 14.12.3. Steroids 14.12.4. Laser Therapy 14.12.5. Antifungals 14.13. GCC Countries Skin Diseases Treatment Forecast, By Type of Diseases 14.13.1. Autoimmune skin diseases 14.13.2. Genetic skin diseases 14.13.3. Allergic skin diseases 14.13.4. Infectious Skin diseases 14.13.5. Skin cancers 14.14. GCC Countries Skin Diseases Treatment Forecast, By End-Users 14.14.1. Dermatology clinics 14.14.2. Skincare clinics 14.14.3. Hospitals 14.14.4. Aesthetic centres 14.15. South Africa Skin Diseases Treatment Forecast, By Product Type 14.15.1. Medicated creams and Ointments 14.15.2. Antibiotics and Vitamins 14.15.3. Steroids 14.15.4. Laser Therapy 14.15.5. Antifungals 14.16. South Africa Skin Diseases Treatment Forecast, By Type of Diseases 14.16.1. Autoimmune skin diseases 14.16.2. Genetic skin diseases 14.16.3. Allergic skin diseases 14.16.4. Infectious Skin diseases 14.16.5. Skin cancers t 14.17. South Africa Skin Diseases Treatment Forecast, By End-Users 14.17.1. Dermatology clinics 14.17.2. Skincare clinics 14.17.3. Hospitals 14.17.4. Aesthetic centres 14.18. Nigeria Skin Diseases Treatment Forecast, By Product Type 14.18.1. Medicated creams and Ointments 14.18.2. Antibiotics and Vitamins 14.18.3. Steroids 14.18.4. Laser Therapy 14.18.5. Antifungals 14.19. Nigeria Skin Diseases Treatment Forecast, By Type of Diseases 14.19.1. Autoimmune skin diseases 14.19.2. Genetic skin diseases 14.19.3. Allergic skin diseases 14.19.4. Infectious Skin diseases 14.19.5. Skin cancers 14.20. Nigeria Skin Diseases Treatment Forecast, By End-Users 14.20.1. Dermatology clinics 14.20.2. Skincare clinics 14.20.3. Hospitals 14.20.4. Aesthetic centres 14.21. Egypt Skin Diseases Treatment Forecast, By Product Type 14.21.1. Medicated creams and Ointments 14.21.2. Antibiotics and Vitamins 14.21.3. Steroids 14.21.4. Laser Therapy 14.21.5. Antifungals 14.22. Egypt Skin Diseases Treatment Forecast, By Type of Diseases 14.22.1. Autoimmune skin diseases 14.22.2. Genetic skin diseases 14.22.3. Allergic skin diseases 14.22.4. Infectious Skin diseases 14.22.5. Skin cancers 14.23. Egypt Skin Diseases Treatment Forecast, By End-Users 14.23.1. Dermatology clinics 14.23.2. Skincare clinics 14.23.3. Hospitals 14.23.4. Aesthetic centres 14.24. Rest of Middle East & Africa Skin Diseases Treatment Forecast, By Product Type 14.24.1. Medicated creams and Ointments 14.24.2. Antibiotics and Vitamins 14.24.3. Steroids 14.24.4. Laser Therapy 14.24.5. Antifungals 14.25. Rest of Middle East & Africa Skin Diseases Treatment Forecast, By Type of Diseases 14.25.1. Autoimmune skin diseases 14.25.2. Genetic skin diseases 14.25.3. Allergic skin diseases 14.25.4. Infectious Skin diseases 14.25.5. Skin cancers 14.26. Rest of Middle East & Africa Skin Diseases Treatment Forecast, By End-Users 14.26.1. Dermatology clinics 14.26.2. Skincare clinics 14.26.3. Hospitals 14.26.4. Aesthetic centres 14.27. Middle East & Africa Skin Diseases Treatment Attractiveness Analysis 14.27.1. By Product Type 14.27.2. By Type of Diseases 14.27.3. By End-Users 14.28. PEST Analysis 14.29. Key Trends 14.30. Key Developments 15. South America Skin Diseases Treatment Analysis 15.1. Key Findings 15.2. South America Skin Diseases Treatment Overview 15.3. South America Skin Diseases Treatment Value Share Analysis, By Product Type 15.4. South America Skin Diseases Treatment Forecast, By Product Type 15.4.1. Medicated creams and Ointments 15.4.2. Antibiotics and Vitamins 15.4.3. Steroids 15.4.4. Laser Therapy 15.4.5. Antifungals 15.5. South America Skin Diseases Treatment Value Share Analysis, By Type of Diseases 15.6. South America Skin Diseases Treatment Forecast, By Type of Diseases 15.6.1. Autoimmune skin diseases 15.6.2. Genetic skin diseases 15.6.3. Allergic skin diseases 15.6.4. Infectious Skin diseases 15.6.5. Skin cancers 15.7. South America Skin Diseases Treatment Value Share Analysis, By End-Users 15.8. South America Skin Diseases Treatment Forecast, By End-Users 15.8.1. Dermatology clinics 15.8.2. Skincare clinics 15.8.3. Hospitals 15.8.4. Aesthetic centres 15.9. South America Skin Diseases Treatment Value Share Analysis, By Country 15.10. South America Skin Diseases Treatment Forecast, By Country 15.10.1. Brazil 15.10.2. Colombia 15.10.3. Argentina 15.10.4. Rest of South America 15.11. South America Skin Diseases Treatment Analysis, By Country 15.12. Brazil Skin Diseases Treatment Forecast, By Product Type 15.12.1. Medicated creams and Ointments 15.12.2. Antibiotics and Vitamins 15.12.3. Steroids 15.12.4. Laser Therapy 15.12.5. Antifungals 15.13. Brazil Skin Diseases Treatment Forecast, By Type of Diseases 15.13.1. Autoimmune skin diseases 15.13.2. Genetic skin diseases 15.13.3. Allergic skin diseases 15.13.4. Infectious Skin diseases 15.13.5. Skin cancers 15.14. Brazil Skin Diseases Treatment Forecast, By End-Users 15.14.1. Dermatology clinics 15.14.2. Skincare clinics 15.14.3. Hospitals 15.14.4. Aesthetic centres 15.15. Colombia Skin Diseases Treatment Forecast, By Product Type 15.15.1. Medicated creams and Ointments 15.15.2. Antibiotics and Vitamins 15.15.3. Steroids 15.15.4. Laser Therapy 15.15.5. Antifungals 15.16. Colombia Skin Diseases Treatment Forecast, By Type of Diseases 15.16.1. Autoimmune skin diseases 15.16.2. Genetic skin diseases 15.16.3. Allergic skin diseases 15.16.4. Infectious Skin diseases 15.16.5. Skin cancers 15.17. Colombia Skin Diseases Treatment Forecast, By End-Users 15.17.1. Dermatology clinics 15.17.2. Skincare clinics 15.17.3. Hospitals 15.17.4. Aesthetic centres 15.18. Argentina Skin Diseases Treatment Forecast, By Product Type 15.18.1. Medicated creams and Ointments 15.18.2. Antibiotics and Vitamins 15.18.3. Steroids 15.18.4. Laser Therapy 15.18.5. Antifungals 15.19. Argentina Skin Diseases Treatment Forecast, By Type of Diseases 15.19.1. Autoimmune skin diseases 15.19.2. Genetic skin diseases 15.19.3. Allergic skin diseases 15.19.4. Infectious Skin diseases 15.19.5. Skin cancers 15.20. Argentina Skin Diseases Treatment Forecast, By End-Users 15.20.1. Dermatology clinics 15.20.2. Skincare clinics 15.20.3. Hospitals 15.20.4. Aesthetic centres 15.21. Rest of South America Skin Diseases Treatment Forecast, By Product Type 15.21.1. Medicated creams and Ointments 15.21.2. Antibiotics and Vitamins 15.21.3. Steroids 15.21.4. Laser Therapy 15.21.5. Antifungals 15.22. Rest of South America Skin Diseases Treatment Forecast, By Type of Diseases 15.22.1. Autoimmune skin diseases 15.22.2. Genetic skin diseases 15.22.3. Allergic skin diseases 15.22.4. Infectious Skin diseases 15.22.5. Skin cancers 15.23. Rest of South America Skin Diseases Treatment Forecast, By End-Users 15.23.1. Dermatology clinics 15.23.2. Skincare clinics 15.23.3. Hospitals 15.23.4. Aesthetic centres 15.24. South America Skin Diseases Treatment Attractiveness Analysis 15.24.1. By Product Type 15.24.2. By Type of Diseases 15.24.3. By End-Users 15.25. PEST Analysis 15.26. Key Trends 15.27. Key Developments 16. Company Profiles 16.1. Market Share Analysis, By Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players By price, presence, market share, Component, and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A By Regions, Investment and Component 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Pfizer Inc. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Allergen Plc. 16.3.3. Celgene Corporation 16.3.4. Abbvie Inc. 16.3.5. Eli Lilly and Company 16.3.6. GlaxoSmithKline Plc. 16.3.7. Galderma 16.3.8. Incyte corporation 16.3.9. Valeant Pharmaceuticals International Inc. 16.3.10. Almirall S.A. 16.3.11. Bayer AG 16.3.12. Johnson & Johnson 16.3.13. Novartis AG 16.3.14. AstraZeneca 16.3.15. Amgen Inc. 16.3.16. Merck KGaA 16.3.17. Cipher pharmaceuticals 16.3.18. Janssen biotech 16.3.19. Kaken Pharmaceuticals 16.3.20. Regeneron pharmaceuticals Inc.